Inactivation of DAB2IP by promoter methylation occurs in several malignancies, including prostate and breast cancer [34], and it has been shown to modulate epithelial-to-mesenchymal transition and prostate-cancer metastasis [35]. The gene discussed is DAB2IP; the disease is breast cancer.